questionsmedicales.fr
Mélanges complexes
Produits biologiques
Ménotropines
Ménotropines : Questions médicales fréquentes
Diagnostic
5
Insuffisance ovarienne
Dosage hormonal
Infertilité
Troubles ovulatoires
Cycles menstruels
Infertilité
Suivi hormonal
Échographie
Symptômes
5
Ovulation
Douleurs pelviennes
Effets secondaires
Nausées
Hyperstimulation ovarienne
Gonflement abdominal
Infertilité
Douleurs pelviennes
Grossesse multiple
Nausées
Prévention
5
Prévention
Hyperstimulation ovarienne
Bilan de santé
Antécédents médicaux
Grossesse multiple
Surveillance
Évaluation des risques
Spécialiste de la fertilité
Traitements
5
Durée du traitement
Réponse ovarienne
Agonistes de la GnRH
Antagonistes de la GnRH
Induction de l'ovulation
Production d'ovules
Complications
5
Complications
Hyperstimulation ovarienne
Infections
Réactions allergiques
Prévention
Suivi régulier
Signes d'alerte
Douleurs abdominales
Facteurs de risque
5
Infertilité
Troubles hormonaux
Antécédents médicaux
Chirurgie pelvienne
Tabagisme
Réserve ovarienne
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Ménotropines : Questions médicales les plus fréquentes",
"headline": "Ménotropines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Ménotropines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-24",
"dateModified": "2026-08-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Ménotropines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Produits biologiques",
"url": "https://questionsmedicales.fr/mesh/D001688",
"about": {
"@type": "MedicalCondition",
"name": "Produits biologiques",
"code": {
"@type": "MedicalCode",
"code": "D001688",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D20.215"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Ménotropines",
"alternateName": "Menotropins",
"code": {
"@type": "MedicalCode",
"code": "D008596",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Gaurang S Daftary",
"url": "https://questionsmedicales.fr/author/Gaurang%20S%20Daftary",
"affiliation": {
"@type": "Organization",
"name": "Ferring Pharmaceuticals, Inc., Parsippany, New Jersey."
}
},
{
"@type": "Person",
"name": "Patrick W Heiser",
"url": "https://questionsmedicales.fr/author/Patrick%20W%20Heiser",
"affiliation": {
"@type": "Organization",
"name": "Ferring Pharmaceuticals, Inc., Parsippany, New Jersey. Electronic address: Patrick.Heiser@ferring.com."
}
},
{
"@type": "Person",
"name": "Muhammad Wajahat Ameer",
"url": "https://questionsmedicales.fr/author/Muhammad%20Wajahat%20Ameer",
"affiliation": {
"@type": "Organization",
"name": "Department of Fisheries, Government of Punjab, Rajanpur, 33500, Pakistan."
}
},
{
"@type": "Person",
"name": "Farhat Jabeen",
"url": "https://questionsmedicales.fr/author/Farhat%20Jabeen",
"affiliation": {
"@type": "Organization",
"name": "Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad, Faisalabad, Pakistan. farjabeen2004@yahoo.co.in."
}
},
{
"@type": "Person",
"name": "Muhammad Asad",
"url": "https://questionsmedicales.fr/author/Muhammad%20Asad",
"affiliation": {
"@type": "Organization",
"name": "Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad, Faisalabad, Pakistan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "IVF protocol efficacy in women with expected suboptimal response depending on ovary stimulation mode.",
"datePublished": "2021-00-00",
"url": "https://questionsmedicales.fr/article/34937512",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/09513590.2021.2006526"
}
},
{
"@type": "ScholarlyArticle",
"name": "Gonadotropin treatment for male partial congenital hypogonadotropic hypogonadism in Chinese patients.",
"datePublished": null,
"url": "https://questionsmedicales.fr/article/31464203",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4103/aja.aja_88_19"
}
},
{
"@type": "ScholarlyArticle",
"name": "First pre-filled pen device with highly purified human menopausal gonadotropin (HP-hMG, Menopur) in liquid is shown to be bioequivalent to powder for reconstitution.",
"datePublished": "2021-Dec-00",
"url": "https://questionsmedicales.fr/article/34622768",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5414/CP204040"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Timing of HMG supplementation and clinical outcomes of advanced-age patients with diminished ovarian reserve receiving gonadotropin-releasing hormone antagonist protocol].",
"datePublished": "2021-Mar-25",
"url": "https://questionsmedicales.fr/article/33849833",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.12122/j.issn.1673-4254.2021.03.14"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clomiphene citrate mild stimulation improved follicular development outcomes in PCOS women with high luteinizing hormone and poor ovarian response: A case report.",
"datePublished": "2022-Oct-21",
"url": "https://questionsmedicales.fr/article/36281179",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MD.0000000000031323"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Mélanges complexes",
"item": "https://questionsmedicales.fr/mesh/D045424"
},
{
"@type": "ListItem",
"position": 3,
"name": "Produits biologiques",
"item": "https://questionsmedicales.fr/mesh/D001688"
},
{
"@type": "ListItem",
"position": 4,
"name": "Ménotropines",
"item": "https://questionsmedicales.fr/mesh/D008596"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Ménotropines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Ménotropines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-09-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Ménotropines",
"description": "Comment diagnostiquer une insuffisance ovarienne ?\nQuels tests pour évaluer la réserve ovarienne ?\nQuand prescrire des ménotropines ?\nQuels signes indiquent un besoin de ménotropines ?\nComment évaluer la réponse au traitement ?",
"url": "https://questionsmedicales.fr/mesh/D008596#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Ménotropines",
"description": "Quels symptômes d'une ovulation irrégulière ?\nQuels effets secondaires des ménotropines ?\nComment reconnaître une hyperstimulation ovarienne ?\nQuels symptômes d'infertilité chez la femme ?\nQuels signes d'une grossesse multiple ?",
"url": "https://questionsmedicales.fr/mesh/D008596#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Ménotropines",
"description": "Comment prévenir l'hyperstimulation ovarienne ?\nQuelles précautions avant le traitement ?\nComment réduire les risques de grossesse multiple ?\nQuels conseils pour une fertilité optimale ?\nComment évaluer les risques avant traitement ?",
"url": "https://questionsmedicales.fr/mesh/D008596#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Ménotropines",
"description": "Comment les ménotropines sont-elles administrées ?\nQuelle est la durée du traitement par ménotropines ?\nQuels médicaments combinés avec les ménotropines ?\nComment surveiller le traitement ?\nQuels sont les objectifs du traitement ?",
"url": "https://questionsmedicales.fr/mesh/D008596#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Ménotropines",
"description": "Quelles complications possibles des ménotropines ?\nComment gérer l'hyperstimulation ovarienne ?\nQuels risques liés aux injections ?\nComment prévenir les complications ?\nQuels signes d'alerte après traitement ?",
"url": "https://questionsmedicales.fr/mesh/D008596#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Ménotropines",
"description": "Quels facteurs de risque d'infertilité ?\nComment le poids influence-t-il la fertilité ?\nQuels antécédents médicaux à considérer ?\nQuel rôle joue le tabagisme sur la fertilité ?\nComment le stress impacte-t-il la fertilité ?",
"url": "https://questionsmedicales.fr/mesh/D008596#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une insuffisance ovarienne ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un dosage hormonal et une échographie ovarienne sont nécessaires."
}
},
{
"@type": "Question",
"name": "Quels tests pour évaluer la réserve ovarienne ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par le dosage de l'AMH et la mesure de l'échographie folliculaire."
}
},
{
"@type": "Question",
"name": "Quand prescrire des ménotropines ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont prescrites en cas d'infertilité due à des troubles ovulatoires."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent un besoin de ménotropines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des cycles menstruels irréguliers ou absents peuvent indiquer ce besoin."
}
},
{
"@type": "Question",
"name": "Comment évaluer la réponse au traitement ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La réponse est évaluée par le suivi des niveaux hormonaux et des échographies."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une ovulation irrégulière ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des cycles menstruels irréguliers et des douleurs pelviennes."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires des ménotropines ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des douleurs abdominales et des nausées."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une hyperstimulation ovarienne ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent un gonflement abdominal, des douleurs et des nausées."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'infertilité chez la femme ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des cycles irréguliers, des douleurs pelviennes et des changements hormonaux."
}
},
{
"@type": "Question",
"name": "Quels signes d'une grossesse multiple ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des nausées sévères, un ventre plus gros et des mouvements fœtaux précoces."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hyperstimulation ovarienne ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut un suivi étroit et l'ajustement des doses de ménotropines."
}
},
{
"@type": "Question",
"name": "Quelles précautions avant le traitement ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un bilan de santé complet et une évaluation des antécédents médicaux sont nécessaires."
}
},
{
"@type": "Question",
"name": "Comment réduire les risques de grossesse multiple ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "En ajustant les doses et en surveillant attentivement la réponse ovarienne."
}
},
{
"@type": "Question",
"name": "Quels conseils pour une fertilité optimale ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un poids santé, éviter le tabac et gérer le stress sont essentiels."
}
},
{
"@type": "Question",
"name": "Comment évaluer les risques avant traitement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une consultation avec un spécialiste de la fertilité permet d'évaluer les risques."
}
},
{
"@type": "Question",
"name": "Comment les ménotropines sont-elles administrées ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont généralement administrées par injection sous-cutanée ou intramusculaire."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement par ménotropines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dure généralement de 7 à 14 jours, selon la réponse ovarienne."
}
},
{
"@type": "Question",
"name": "Quels médicaments combinés avec les ménotropines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être combinées avec des agonistes ou antagonistes de la GnRH."
}
},
{
"@type": "Question",
"name": "Comment surveiller le traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement est surveillé par des échographies et des dosages hormonaux réguliers."
}
},
{
"@type": "Question",
"name": "Quels sont les objectifs du traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'objectif est de stimuler la production d'ovules et d'induire l'ovulation."
}
},
{
"@type": "Question",
"name": "Quelles complications possibles des ménotropines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'hyperstimulation ovarienne et les grossesses multiples."
}
},
{
"@type": "Question",
"name": "Comment gérer l'hyperstimulation ovarienne ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut le repos, l'hydratation et parfois une hospitalisation."
}
},
{
"@type": "Question",
"name": "Quels risques liés aux injections ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des infections au site d'injection et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier et une communication avec le médecin sont essentiels."
}
},
{
"@type": "Question",
"name": "Quels signes d'alerte après traitement ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs abdominales sévères, des saignements ou des symptômes de grossesse doivent alerter."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque d'infertilité ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge avancé, des antécédents médicaux et des troubles hormonaux."
}
},
{
"@type": "Question",
"name": "Comment le poids influence-t-il la fertilité ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un poids trop bas ou trop élevé peut perturber les cycles menstruels et l'ovulation."
}
},
{
"@type": "Question",
"name": "Quels antécédents médicaux à considérer ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de maladies hormonales ou de chirurgie pelvienne sont importants."
}
},
{
"@type": "Question",
"name": "Quel rôle joue le tabagisme sur la fertilité ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme peut réduire la réserve ovarienne et affecter la qualité des ovules."
}
},
{
"@type": "Question",
"name": "Comment le stress impacte-t-il la fertilité ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut perturber les cycles hormonaux et affecter l'ovulation."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 12/08/2026
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Ferring Pharmaceuticals, Inc., Parsippany, New Jersey.
Publications dans "Ménotropines" :
2 publications dans cette catégorie
Affiliations :
Ferring Pharmaceuticals, Inc., Parsippany, New Jersey. Electronic address: Patrick.Heiser@ferring.com.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Fisheries, Government of Punjab, Rajanpur, 33500, Pakistan.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad, Faisalabad, Pakistan. farjabeen2004@yahoo.co.in.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad, Faisalabad, Pakistan.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad, Faisalabad, Pakistan.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad, Faisalabad, Pakistan.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad, Faisalabad, Pakistan.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad, Faisalabad, Pakistan.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry, Government College University Faisalabad, Faisalabad, Pakistan.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad, Faisalabad, Pakistan.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Eastern Medicine, Government College University Faisalabad, Faisalabad, Pakistan.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Eastern Medicine, Government College University Faisalabad, Faisalabad, Pakistan. makram_0451@hotmail.com.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Obstetrics and Gynecology, National Taiwan University Hospital, Yunlin Branch, Douliou, Taiwan.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan; Livia Shangyu Wan Scholarship, National Taiwan University, Taipei, Taiwan.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: sheeuan@ntu.edu.tw.
Publications dans "Ménotropines" :
1 publication dans cette catégorie
Affiliations :
Hospital Israelita Albert Einstein, São Paulo, Brazil. oscar.filho@vidabemvinda.com.br.
Clínica VidaBemVinda, São Paulo, Brazil. oscar.filho@vidabemvinda.com.br.
Publications dans "Ménotropines" :
IVF protocol efficacy estimation in women with expected suboptimal response depending on ovary stimulation mode....
A randomized controlled study embracing results of 51 IVF cycle in women with ovary suboptimal response. The suboptimal response prognostic analysis was performed basing on ≤9 oocyte cumulus complexes...
The total gonadotropin dose in Group II patients was authentically lower compared to Group I (...
Corifollitropin alfa administration combined with highly purified menotropin in IVF cycles for suboptimal responders is quite effective, however, this strategy has no preference over other stimulation...
Partial congenital hypogonadotropic hypogonadism (PCHH) is caused by an insufficiency in, but not a complete lack of, gonadotropin secretion. This leads to reduced testosterone production, mild testic...
To determine whether serum human follicle-stimulating hormone (FSH) levels after single subcutaneous dosing of highly purified human menopausal gonadotropins (HP-hMG) in a liquid formulation and a pow...
This was a randomized, two-way, crossover, single-dose, bioequivalence trial comparing Menopur liquid injected by pre-filled pen, with Menopur powder injected by conventional syringe and needle. The p...
In total, 76 women were randomized, and 56 completed the trial. The mean FSH and hCG serum concentration-time profiles were comparable between the two HP-hMG formulations. The geometric mean ratios an...
The 90% CIs for the geometric mean ratios of serum FSH AUC...
To assess the effect and timing of human menopausal gonadotropin (HMG) supplementation in advancedage patients with diminished ovarian reserve (DOR) receiving gonadotropin-releasing hormone antagonist...
A total of 682 patients with DOR aged over 35 years undergoing IVF-ET treatment were included in this study. All the patients underwent a GnRH antagonist protocol, and controlled ovarian stimulation w...
The 3 groups showed no significant difference in hCG trigger day E2 and P levels, endometrial thickness, or the number of follicles with comparable fertilization rate and cleavage rate (...
HMG supplementation in the middle and late follicular phase can improve the outcomes of controlled ovarian hyperstimulation and increase the clinical pregnancy rate of fresh embryo transfer cycle in a...
Polycystic ovary syndrome (PCOS) is a main cause of anovulatory infertility in women of reproductive age. About 30% to 50% of patients with PCOS has high serum basal luteinizing hormone (LH) levels, a...
A 28-year-old PCOS woman with high basal LH levels, underwent IVF assisted pregnancy treatment in our hospital, whom canceled due to POR during two traditional controlled ovulation induction program. ...
This patient with the diagnosis of PCOS was undergone IVF assisted pregnancy treatment in our hospital....
CC protocol supports the development of follicular....
CC protocol resulted in better follicular development and high-quality embryos due to the continuous maintenance of an elevated LH levels....
PCOS women with poor ovarian response required relatively higher LH to maintain the normal development of follicles....
To compare the effects of letrozole and human menopausal gonadotropin (HMG) in the treatment of patients with polycystic ovary syndrome (PCOS) resistant to clomiphene citrate (CC)....
A total of 96 clomiphene resistance polycystic ovary syndrome patients infertility were randomly divided into an LE group, and HMG group (n = 48). LE group orally received letrozole at 5.0 mg/d on the...
There was no significant difference in the number of ovulation cycles between the 2 groups (53.6% vs 64.7%, P > .05). The number of mature follicular cycles in the HMG group was higher than that of th...
Letrozole-induced ovulation can obtain ovulation rate and pregnancy rate similar to gonadotropin, but reduce the risk associated with treatment. It can be used as an effective ovulation option for pat...
At present, the precise role of human menopausal gonadotropin (HMG) and recombinant luteinizing hormone (rLH) supplementation at an early time of follicular phase on in vitro fertilization (IVF)/intra...
To compare the efficacies of gonadotropin-releasing hormone (GnRH) pulse subcutaneous infusion with combined human chorionic gonadotropin and human menopausal gonadotropin (HCG/HMG) intramuscular inje...
In total, 220 idiopathic/isolated HH patients were divided into the GnRH pulse therapy and HCG/HMG combined treatment groups (n = 103 and n = 117, respectively). The luteinizing hormone and follicle-s...
In the GnRH group and HCG/HMG group, the testosterone level and testicular volume at the 6-month follow-up session were significantly higher than were those before treatment. There were 62 patients (6...
The GnRH pulse subcutaneous infusion successfully treated male patients with HH, leading to earlier sperm production than that in the HCG/HMG-treated patients. GnRH pulse subcutaneous infusion is a pr...
To evaluate the value of using both HMG and recombinant FSH (r-FSH) in the GnRH antagonist protocol for women with high AMH....
This retrospective, single-center cohort study was conducted from January 2013 to December 2018. Of 277 GnRH antagonist IVF/ICSI cycles in women with anti-Mullerian hormone (AMH) ≥5 μg/L, 170 cycles r...
We observed significantly lower serum LH levels in the r-FSH + HMG groups during ovarian stimulation. The serum estradiol and progesterone levels were lower in the r-FSH + HMG groups on the trigger da...
HMG for LH supplementation in the GnRH antagonist protocol for patients with high AMH is not significantly superior to r-FSH alone in terms of ovarian response and pregnancy outcome. Nevertheless, HMG...
Optimising controlled ovarian stimulation (COS) procedures for in vitro fertilisation (IVF) requires an assessment of the patients' medical history, ovarian reserve, prognostic factors and resources t...
In this single-centre, retrospective, non-interventional study of 20 infertility patients, each individual was provided with a personalised COS regimen based on her ovarian reserve biomarker-serum ant...
Following a mean COS duration of 11 days and 50% of patients who underwent frozen embryo transfers, the CPR per started cycle was 70%. The observed CPR from this study was higher than that reported in...
The present study provides a first glimpse into the favourable benefit: risk profile of a mixed protocol regimen using follitropin delta combined with HP-hMG in a cohort of Asian patients in Malaysia....